SMMT - Summit Therapeutics plc
| Previous Close | 1.85 |
| Open | 1.90 |
| Bid | 0.00 x 4000 |
| Ask | 2.50 x 900 |
| Day's Range | 1.85 - 1.95 |
| 52 Week Range | 1.85 - 15.90 |
| Volume | 27,054 |
| Avg. Volume | 126,004 |
| Market Cap | 32.4M |
| Beta (3Y Monthly) | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.79 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- GlobeNewswire•5 days ago
Summit Therapeutics to Participate in Upcoming Investor Events
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Participate in Upcoming Investor Events Oxford, UK, and Cambridge, MA, US, 10 October 2018.
- GlobeNewswire•7 days ago
Surrender of Share Options
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that UK-based Executive Director and PDMRs, and employees have voluntarily surrendered options to subscribe for a total of 5,532,461 of the Company’s ordinary shares of one penny nominal value. Following the surrender, the total number of share options which remains outstanding is 3,073,330 (representing 3.7% of the Company’s issued share capital).
- Simply Wall St.•20 days ago
Can Summit Therapeutics plc (LON:SUMM) Continue To Outperform Its Industry?
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. SummitRead More...
- GlobeNewswire•25 days ago
Summit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2018 and Operational Progress. Oxford, UK, and Cambridge, MA, US, 20 September 2018- Summit Therapeutics ...
- GlobeNewswire•last month
Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018. Oxford, UK, and Cambridge, MA, US, 14 September 2018- Summit Therapeutics plc, ...
- GlobeNewswire•last month
Summit Therapeutics to Participate in Upcoming Investor Conferences
Summit Therapeutics to Participate in Upcoming Investor Conferences. Oxford, UK, and Cambridge, MA, US, 14 September 2018– Summit Therapeutics plc announces that management will participate in one on one ...
- GlobeNewswire•last month
Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
Summit Therapeutics plc Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets. Discovery Enabled by Discuva Platform and Proprietary Bacterial Libraries Oxford, UK, ...
- GlobeNewswire•last month
Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that it has nominated SMT-571 as its lead clinical candidate from its first gonorrhoea series. New mechanism antibiotics are important in the fight against gonorrhoea, as the pathogen is becoming increasingly resistant to the only recommended treatment option. Just last week, the US Centers for Disease Control and Prevention (‘CDC’) reported preliminary data that gonorrhoea cases in the US increased by 67% between 2013 and 2017 and with resistant cases on the rise, the CDC stated that additional treatment options for gonorrhoea are urgently needed.
- GlobeNewswire•last month
Total voting rights
Oxford, UK, and Cambridge, MA, US 3 September 2018– Summit Therapeutics plc, announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6. 1, the Company's issued share capital as at ...
- GlobeNewswire•2 months ago
Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 29, 2018-- Summit Therapeutics plc announces that Mr Glyn Edwards, Chief Executive Officer, will present on the Company’ s plans to advance its new mechanism ...
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Ballard Power, Reading International, Odonate Therapeutics, Stitch Fix, Summit Therapeutics, and Cellectis S.A — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ballard ...
- GlobeNewswire•2 months ago
Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), a leader in antibiotic innovation, today announces that it has been awarded an additional $12 million under its contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response. The funds will support the Phase 3 development programme for ridinilazole, the Company’s precision new mechanism antibiotic for the treatment of C. difficile infection (‘CDI’). “BARDA’s continued support underlines the promise ridinilazole has as a potential front-line CDI treatment option which can treat the initial infection and address the key clinical issue of recurrent disease,” commented Mr Glyn Edwards, Chief Executive Officer of Summit.
- GlobeNewswire•2 months ago
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 06, 2018-- Summit Therapeutics plc announces that Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on 9 August ...
- GlobeNewswire•2 months ago
Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces today the publication in the journal PLOS ONE of microbiome analyses highlighting ridinilazole as a precision antibiotic in development for the treatment of C. difficile infection (‘CDI’). The clinical management of CDI is stymied by poor sustained cures due to high recurrence rates after initial infection. In a double-blind Phase 2 clinical trial, ridinilazole was highly preserving of patients’ microbiomes compared to patients treated with the broad-spectrum standard of care antibiotic vancomycin.
- PR Newswire•3 months ago
Summit Therapeutics Joins Antimicrobials Working Group
WASHINGTON , July 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM) (Summit) to its coalition of companies ...
- Zacks•3 months ago
Summit Therapeutics Enters Oversold Territory
Summit Therapeutics Enters Oversold Territory
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Aquinox Pharmaceuticals and Summit Therapeutics
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Aquinox Pharmaceuticals and Summit Therapeutics both saw their shares dramatically drop on Wednesday after each company announced failed trial results. Aquinox Pharmaceuticals, Inc. shares closed down almost 85% on Wednesday and hit a new low of $2.25 on about 14.2 million shares traded. The company revealed that late-stage trial results for its bladder pain drug failed to perform better than the placebo in patients.
